National Institute of Neurological Disorders and Stroke (NINDS)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).
National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.
National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.
Top-decile sponsor footprint
National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
567 total, page 6 of 12
Brain Excitability in Patients With Succinic Semialdehyde Dehydrogenase Deficiency
NCT00132366
Deep Brain Stimulation to Treat Cervical Dystonia
NCT00132340
Mirroring a Movement
NCT00123448
Neuropathology of Spasmodic Dysphonia
NCT00118586
Interhemispheric Plasticity in Humans
NCT00120666
Double Blind Trial of DC Polarization in FTD
NCT00117858
MRI Measurement of Brain Metabolism Across the Sleep-Wake Cycle
NCT00117221
Motor Performance in Chronic Stroke Patients
NCT00110175
Effects of Two Different Kinds of Exercise on Stroke Rehabilitation
NCT00108680
Talampanel to Treat Parkinson's Disease
NCT00108667
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
NCT00106912
Transcranial Electrical Polarization to Treat Focal Hand Dystonia
NCT00106782
Deep Brain Stimulation for Cervical Dystonia
NCT00105430
Genetic Characterization of Parkinson's Disease
NCT00105131
Nitrite Infusion in Healthy Volunteers
NCT00103025
Effect of Surface Electrical Stimulation on Movement of the Larynx
NCT00104000
Brain Function in Focal Dystonia
NCT00102999
Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor
NCT00102596
Brain Reorganization Following Constraint-Induced Therapy in Children With Cerebral Palsy
NCT00100503
Biomarkers in Multiple Sclerosis
NCT00325988
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
NCT00099307
Safety Study of Interferon Beta 1a to for Acute Stroke
NCT00097318
Brain Activities Associated With Different Facial Expressions Using Blood Oxygenation Level Dependent Functional MRI
NCT00096564
Non-Pharmacologic Therapy for Neurocardiogenic Syncope
NCT00096902
Replagal Enzyme Replacement Therapy for Adults With Fabry Disease
NCT00097890
The Functional Anatomy of Personality Trait Knowledge: An fMRI Study
NCT00095407
Propranolol to Treat Fainting in Children With Sympathoadrenal Imbalance
NCT00093860
Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease
NCT00095355
Neural Correlates of Observation of Tactile Stimulation in Healthy Subjects
NCT00091533
Rituximab to Treat Stiff Person Syndrome
NCT00091897
Lisuride Patch to Treat Parkinson's Disease
NCT00089622
Treatment Study of Frontotemporal Dementia
NCT00088751
Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors
NCT00088400
Effect of Lithium and Divalproex in Alzheimer's Disease
NCT00088387
Effect of Direct Current Polarization on Brain Function
NCT00088569
Biological Markers in Parkinson's Disease
NCT00088335
ACP-103 to Treat Parkinson's Disease
NCT00086294
Brain Electrical Stimulation to Enhance Recovery After Stroke
NCT00085657
Herpes Virus-6 and Epilepsy
NCT00085683
Observational Learning in Stroke Patients
NCT00083642
Role of the Brain in Making Economic Decisions
NCT00083317
Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives
NCT00082615
Pelvic Pain in Women With Endometriosis
NCT00073801
Language and Emotional Function in Patients With Temporal Lobe Epilepsy
NCT00081432
Timing of Voluntary Movement in Patients With Tourette Syndrome and Chronic Tic Disorder
NCT00081419
Timing of Voluntary Movement in Patients With Schizophrenia
NCT00080548
Brain Physiology in Polio Survivors
NCT00080600
Rhythm Perception and Generation
NCT00080067
Octanol to Treat Essential Tremor
NCT00080366
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
NCT00079768
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 80 |
| Phase 2 | 78 |
| Phase 3 | 11 |
| Phase 4 | 5 |
Therapeutic Areas
What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline
48 recruiting of 567 indexed (8% open); 467 completed (82%).
Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).
Top condition: Healthy (23 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide
Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 567 trials (± recruiting share)
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
Sponsors near 8% open enrollment (± trial volume)
- National Jewish Health · 8% recruiting · 83 trials
- ACADIA Pharmaceuticals · 9% recruiting · 35 trials
- Texas Tech University Health Sciences Center, El Paso · 9% recruiting · 35 trials
- Boehringer Ingelheim · 8% recruiting · 515 trials
Related
What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page
567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.
- 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.